Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

Patent Assigned to Enanta Pharmaceuticals, Inc.

Spiropyrrolidine derived antiviral agents
Patent number: 11976084
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 22, 2021
Date of Patent: May 7, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

What are the benefits of pyrrolidine?
Pyrrolidines are very important nitrogen-containing heterocycles. It has glucosidase inhibitory activity, along with antiviral, antibacterial, antidiabetic, and anticancer activities.